Could a new pill curb meth cravings? early trial launches
NCT ID NCT06989853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called troiluzole can reduce the appeal of methamphetamine for people with methamphetamine use disorder. About 40 adults who use meth but are not seeking treatment will take the drug and then choose between meth and money in a lab setting. The goal is to see if troiluzole makes meth less rewarding, which could help control the disorder.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. able to speak/read English, 2. not seeking treatment for drug use at the time of the study, 3. female or male between the ages of 18 and 55 years, 4. recent methamphetamine use verified by methamphetamine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for MUD, 5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for MUD (and OUD for the co-morbid MUD and OUD group, see below) at the time of screening, 6. ECG, read by a cardiologist, within normal limits, 7. females using an effective form of birth control and not pregnant or breastfeeding, 8. no known contraindications (e.g., hepatic disease \[save for asymptomatic HCV status as cleared by study physician\]) or allergies to troriluzole. Individuals in the MUD and OUD group must also report recent opioid use, verified by opioid positive urine, as well as fulfillment of DSM-5 diagnostic criteria for OUD with physiologic dependence (determined to not be physically dependent if a participant arrives with a urine sample for drug screening that is negative for a short-acting opioid and does not have a score of 5 or greater on the clinical opioid withdrawal scale \[COWS\]). Exclusion Criteria: 1. unable to speak/read English, 2. seeking treatment for drug use, 3. under 18 years or over 55 years, 4. no recent methamphetamine use as indicated by methamphetamine negative urine and no DSM-5 diagnosis of MUD, 5. judged to be medically and psychiatrically unhealthy by study physicians at the time of screening, 6. ECG, read by a cardiologist, outside normal limits, 7. females not using an effective form of birth control or pregnant or breastfeeding, 8. blood pressure readings indicative of hypertension (i.e., blood pressure \> 140/90 mmHg) on 2 consecutive screening visits, 9. BMI \< 18 or \> 30; weight \< 50 kg, 10. taking any medications prescribed by a physician for a chronic condition, 11. any laboratory chemistry values (e.g., LFTs) \> 3 times normal at screening or during admission, 12. history of serious physical disease or diagnosis of any disorder (e.g., current hepatic disease \[save for asymptomatic HCV status; as noted above\], histories of seizure, diabetes, asthma or CNS tumors) or current or past histories of psychiatric disorder, including current or recent suicidal ideation that would limit compliance in the study, other than MUD or tobacco use disorder (and OUD for the co-morbid MUD/OUD group only) that in the opinion of the study physicians would interfere with participation and 13. contraindications (e.g., hepatic disease) or allergies to troriluzole.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Psychopharmacology of Addiction Laboratory
RECRUITINGLexington, Kentucky, 40507, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes and Weight-Loss drug help people quit meth?
- Can methadone clinics double as meth treatment centers?
- Brain zaps aimed at craving center could help break meth addiction
- Brain zaps synced to brain waves may curb meth cravings
- Can a single psilocybin dose help break meth addiction?
- Can a psychedelic help break meth addiction in people with HIV?